Sage Therapeutics - SAGE EV/Sales Multiple

Official company branding of Sage Therapeutics Inc. (SAGE)

Sage Therapeutics, Inc. (SAGE) is a recognized expert in neuromedicine dedicated to returning patients to a full life. The company is focused on the market launch of its unique oral medication, Zurzuvae. Asset value growth is supported by a partnership with Biogen and the expansion of insurance coverage. The company's EV-to-revenue ratio visualizes market expectations, where reflects the baseline metric level, adjusted for the impact of debt load.

SAGE - Sage Therapeutics EV/Sales Multiple over the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Sage Therapeutics (SAGE)

- cash balance and cash flow data:
Fundamental company valuation:SAGE (Sage Therapeutics, Inc.)
Mass-produced product of sagerx.com

Investors must determine the fair value of the asset by analyzing the enterprise value to revenue ratio. Evaluating Sage Therapeutics, Inc. (SAGE) via EV/Sales allows for the identification of whether the business is overvalued or undervalued, which is critical for Sage Therapeutics, Inc. (SAGE), as its financial stability currently depends entirely on the commercial success of a single drug within a narrow neurological segment.

Competitor analysis for Sage Therapeutics, Inc.

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|KTTA: Company Value to Revenue|Business Value to Revenue CRGT (cortigent.com)|ATXI: EV/Sales Multiple|BCLI (BrainStorm Cell Therapeutics) - Enterprise Value-to-Revenue Ratio|CARA (Cara Therapeutics Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio CHRO|Company Value to Revenue ELYM (Eliem Therapeutics)|Enterprise Value-to-Revenue Ratio ITCI (Intra-Cellular Therapies Inc.)|EV/Sales Multiple LBPH (Longboard Pharma)|EV/Sales Multiple Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - EV/Sales Multiple|Business Value to Revenue NRBO (NeuroBo Pharma)|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE